CymaBay Therapeutics Inc  

(Public, NASDAQ:CBAY)   Watch this stock  
Find more results for CBAY
+0.33 (4.13%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.91 - 8.40
52 week 1.46 - 9.40
Open 8.04
Vol / Avg. 563,861.00/537,307.00
Mkt cap 380.02M
P/E     -
Div/yield     -
EPS -1.01
Shares 43.86M
Beta 1.82
Inst. own 70%
Nov 8, 2017
Q3 2017 CymaBay Therapeutics Inc Earnings Call
Nov 8, 2017
Q3 2017 CymaBay Therapeutics Inc Earnings Release
Sep 27, 2017
CymaBay Therapeutics Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sep 26, 2017
CymaBay Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.67% -85.43%
Return on average equity -74.52% -166.42%
Employees 21 -
CDP Score - -


7999 Gateway Blvd Ste 130
NEWARK, CA 94560-1188
United States - Map
+1-510-2938800 (Phone)
+1-510-2939090 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Officers and directors

Robert James Wills Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Sujal Shah President, Chief Executive Officer
Age: 42
Bio & Compensation  - Reuters
Charles A McWherter Ph.D Senior Vice President, Chief Scientific Officer
Age: 62
Bio & Compensation  - Reuters
Daniel Menold Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
Age: 47
Bio & Compensation  - Reuters
Kirk Rosemark Vice President - Regulatory Affairs and Quality Assurance
Age: 44
Bio & Compensation  - Reuters
Paul T. Quinlan General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Pol F. Boudes M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Robert Booth Ph.D. Director
Bio & Compensation  - Reuters
Caroline Loewy Director
Bio & Compensation  - Reuters
Evan A. Stein M.D. Ph.D. Director
Bio & Compensation  - Reuters